Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Viking Therapeutics, Inc.NASDAQ: VKTX
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -$132.6M, compared with -$74.57M a year earlier. Trailing-twelve-month operating income was -$560.02M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -160.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$132.6M+19.2% QoQ
- Last fiscal yearDec 2025
- -$393.34M-160.6% YoY
- LTMJun 2026
- -$560.02M-163.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.8% | +100.0% | +177.8 pp |
| 1 year | -160.6% | +100.0% | +260.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (393.34M) USD
- Year-over-year change
- -160.6%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (393.34M) | -160.6% |
| FY2024 | 2024-12-31 | (150.92M) | -49.7% |
| FY2023 | 2023-12-31 | (100.83M) | -43.3% |
| FY2022 | 2022-12-31 | (70.36M) | -26.4% |
| FY2021 | 2021-12-31 | (55.68M) | — |
Operating Income vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 operating income of -$560.02M is the lowest of the 7 companies compared; the peer median is -$159.34M.
- Its year-over-year change of -163.1% is the lowest of 6, against a peer median of -4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$3.04M | +87.9% | — | 8.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$73.39M | +4.7% | — | 76.2% |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.34M | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$160.33M | -76.4% | — | — |
| LTM Jun 2026 | -$244.41M | -41.4% | — | 3432.2% | |
| LTM Jun 2026 | -$322.62M | -4.1% | — | 25.1% | |
| LTM Jun 2026 | -$560.02M | -163.1% | — | — | |
| Peer median (excluding VKTX) | -$159.34M | -4.1% | — | 50.7% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 431K |
| Gross Profit | 0 | 0 | 0 | 0 | (431K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Selling, General & Admin | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M |
| Operating Expenses | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| EBITDA | (54.68M) | (68.52M) | (85.52M) | (109.52M) | (359.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (55.68M) | (70.36M) | (100.83M) | (150.92M) | (393.34M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 703K | 1.59M | 15.02M | 40.94M | 33.7M |
| Interest Expense | 18K | 59K | 88K | 94K | 0 |
| Other Income / Expenses | 692K | 1.49M | 14.93M | 40.96M | 33.7M |
| Income Before Tax | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| EPS (Diluted) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| Weighted Avg Shares | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
| Weighted Avg Shares (Diluted) | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.